塔尔克塔马布:第一次批准

相关实验视频

Updated: Jul 15, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Susan J Keam¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs

|October 4, 2023

概括

新型双特异性抗体talquetamab已获得加速批准,用于治疗复发性或耐火性多发性髓瘤 (RRMM). 这标志着瘤学的重大进步,为患有这种具有挑战性的血液癌症的患者提供了新的治疗选择.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
血液学血液学血液学

背景情况:

多发性骨髓瘤 (MM) 是一种血液性恶性瘤,在复发性或耐火性环境中具有显著的未满足需求.
现有的复发性或耐火性多发性髓瘤 (RRMM) 治疗方法存在局限性,需要新的治疗方法.
G蛋白结合受体家族C组5成员D (GPRC5D) 是多发性骨髓瘤治疗的新兴标.

研究的目的:

总结一下talquetamab.b.的关键发展里程碑.
为了突出塔尔克塔马布用于RRMM治疗的监管批准.
为提供talquetamab进入市场的旅程的概述.

主要方法:

对talquetamab的临床前和临床开发数据的审查.
分析美国和欧盟的监管提交和批准.
作为GPRC5D指导的CD3T细胞激活剂,talquetamab的作用机制的总结.

主要成果:

塔尔基塔马布于2023年8月在美国获得了针对RRMM的成年人的加速批准.
塔尔基塔马布于2023年8月在欧盟获得了成人RRMM患者的有条件营销许可.
开发途径涉及重要的临床研究和监管参与.

结论:

塔尔基塔马布代表了复发性或耐火性多发性髓瘤患者的显著治疗进展.
两种特异性抗体的批准强调了在MM治疗中准GPRC5D的潜力.
这一发展标志着先进多发性骨髓瘤管理的新时代.

相关概念视频

01:22

Alzheimer's Disease: Treatment

212

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

212

01:20

Antiepileptic Drugs: Potassium Channel Activators

196

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

196

01:26

Drug Administration and Therapy Phases: Overview

493

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

493